Technical Analysis for NGM - NGM Biopharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 27.06 0.78% 0.21
NGM closed up 0.78 percent on Thursday, April 22, 2021, on 47 percent of normal volume. It ran into resistance at its 50 day moving average. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
Earnings due: May 11
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical NGM trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Doji - Bearish? Reversal 0.00%
20 DMA Resistance Bearish 0.78%
NR7 Range Contraction 3.48%
Up 3 Days in a Row Strength 3.48%
Oversold Stochastic Weakness 3.48%
Shooting Star Candlestick Bearish 3.80%
Older End-of-Day Signals for NGM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1 ATR about 20 hours ago
50 DMA Resistance about 20 hours ago
Up 5% about 20 hours ago
Up 3% about 21 hours ago
Rose Above Previous Day's High about 22 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

NGM Biopharmaceuticals, Inc. Description

NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity. Its products under development also comprise NGM120, an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in preclinical studies to decrease levels of a protein implicated in the dry form of age-related macular degeneration. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp., MedImmune Limited, and JDRF International. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Alcohol Diabetes Pharmacy Monoclonal Antibodies Ophthalmic Macular Degeneration Related Macular Degeneration Insulin Obesity Steatohepatitis Biopharmaceuticals Age Related Macular Degeneration Fibroblast Growth Factor Dimm Fibroblast Growth Factor Receptor Cachexia Gm1 Medimmune Treatment Of Obesity

Is NGM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 32.12
52 Week Low 14.93
Average Volume 219,065
200-Day Moving Average 22.98
50-Day Moving Average 28.04
20-Day Moving Average 27.11
10-Day Moving Average 25.82
Average True Range 1.62
ADX 13.43
+DI 27.74
-DI 21.04
Chandelier Exit (Long, 3 ATRs ) 25.93
Chandelier Exit (Short, 3 ATRs ) 29.10
Upper Bollinger Band 30.49
Lower Bollinger Band 23.73
Percent B (%b) 0.49
BandWidth 24.92
MACD Line -0.61
MACD Signal Line -0.65
MACD Histogram 0.0395
Fundamentals Value
Market Cap 1.87 Billion
Num Shares 69 Million
EPS -0.46
Price-to-Earnings (P/E) Ratio -59.21
Price-to-Sales 16.39
Price-to-Book 5.95
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.15
Resistance 3 (R3) 30.31 29.45 29.64
Resistance 2 (R2) 29.45 28.66 29.37 29.46
Resistance 1 (R1) 28.25 28.17 28.85 28.09 29.29
Pivot Point 27.39 27.39 27.69 27.31 27.39
Support 1 (S1) 26.19 26.60 26.79 26.03 24.83
Support 2 (S2) 25.33 26.11 25.25 24.66
Support 3 (S3) 24.13 25.33 24.49
Support 4 (S4) 23.97